Independent review gives Paradigm’s iPPS program a possible second chance

An independent interim analysis has confirmed statistically significant iPPS benefits in Paradigm’s rest-of-world knee osteoarthritis cohort, giving the company a possible route to continue development despite the overall trial failing its futility test. Any new trial remains subject to funding, creditor approval and regulatory discussions.

  • Independent analysis confirms significant ROW benefits for pain, physical function and patient-reported improvement
  • Overall PARA_OA_012 futility result remains unchanged, with no clear advantage in the full population or US cohort
  • Paradigm plans to assess a new ROW trial as the near-term development priority
  • US development remains possible after further data review and FDA consultation
  • Future trial, funding and restructuring plans remain subject to administration and creditor approval
An image related to Paradigm Biopharmaceuticals Limited A photo of the logo for Paradigm Biopharmaceuticals Add us as a preferred source on Google
Image © middle. Logo © respective owner.

Independent analysis confirms regional iPPS signal

Paradigm Biopharmaceuticals Limited (Administrators Appointed) (ASX:PAR) has found a possible route back into clinical development after an independent review confirmed statistically significant iPPS benefits in the rest-of-world arm of its failed Phase 3 knee osteoarthritis trial.

Shows the Company’s previously reported adjusted wADP changes over time
Caption and image © Paradigm Biopharmaceuticals Limited. From “Independent Review Supports New iPPS ROW Trial”, 19 Nov 2026.
Chart from Paradigm Biopharmaceuticals Limited’s announcement “Independent Review Supports New iPPS ROW Trial”
Image © Paradigm Biopharmaceuticals Limited. From “Independent Review Supports New iPPS ROW Trial”, 19 Nov 2026.
Caption and image © Paradigm Biopharmaceuticals Limited. From “Independent Review Supports New iPPS ROW Trial”, 19 Nov 2026.

TrialKey’s interim analysis found that injectable pentosan polysulfate sodium outperformed placebo at Day 112 for weekly average daily pain, WOMAC physical function and Patient Global Impression of Change among participants in Australia, Hong Kong and Moldova. WOMAC pain also favoured iPPS, although that result was not statistically significant.

At Day 112, the Company’s observed-data analysis showed greater adjusted wADP improvement with iPPS than placebo
Caption and image © Paradigm Biopharmaceuticals Limited. From “Independent Review Supports New iPPS ROW Trial”, 19 Nov 2026.

The findings reinforce Paradigm’s October ROW analysis, which reported a 1.105-point adjusted advantage for iPPS over placebo on the 0-to-10 pain scale among 95 observed assessments. TrialKey used different methods and study populations, so its results are not identical to the company’s earlier analysis, but Paradigm said they were consistent with it.

Overall futility result remains unchanged

The positive regional signal does not overturn PARA_OA_012’s central result. The interim futility outcome remains unchanged, with no clear treatment advantage across the overall study population or in the US cohort.

Physical function over time
Caption and image © Paradigm Biopharmaceuticals Limited. From “Independent Review Supports New iPPS ROW Trial”, 19 Nov 2026.
The Company’s Day 112 analysis also reported differences favouring iPPS for WOMAC function, WOMAC pain and PGIC (nominal p=0.0026, 0.0147 and 0.0032 respective…
Caption and image © Paradigm Biopharmaceuticals Limited. From “Independent Review Supports New iPPS ROW Trial”, 19 Nov 2026.
Caption and image © Paradigm Biopharmaceuticals Limited. From “Independent Review Supports New iPPS ROW Trial”, 19 Nov 2026.

TrialKey’s work was a post-hoc exploratory analysis and was not adjusted for multiple comparisons. The report is also interim, must be reconciled with Paradigm’s official analysis, and may be affected by missing data and analytical assumptions. It did not assess safety, although the company said the independent Data Safety Monitoring Board had found the interim safety profile consistent with earlier iPPS studies.

Potential ROW trial becomes near-term priority

Paradigm now intends to assess a new ROW trial as its near-term priority. The proposed study would use the independent analysis and earlier clinical evidence to shape its design, while addressing lessons around treatment delivery, site oversight and data collection.

That plan is still more pathway than program. Countries, sites, timing, funding and the precise evidence package have not been determined. The company says a potential study would be shaped through discussions with relevant regulators, rather than proceeding on the basis that approval or success is assured.

US development faces operational and regulatory questions

The US has not been ruled out, but it is no longer the immediate focus. TrialKey identified a higher proportion of scheduled injections recorded as not given in the US, alongside gaps in pain records. Paradigm said treatment delivery, data completeness and site performance require further assessment, while noting that no specific cause of the US result has been established.

The company plans to consult the US Food and Drug Administration on the PARA_OA_012 results before deciding whether and how another US study could proceed. Expectations, prior pain treatment, changes in symptoms and differences in care or follow-up may also have influenced the observed responses, according to the review.

Administration remains the immediate constraint

The clinical opportunity sits inside a much less forgiving corporate process. Paradigm’s Phase 3 futility result left the company in voluntary administration, and the board’s proposal to preserve iPPS has not yet been put to creditors for approval.

The proposal combines clinical development, regulatory engagement, funding and restructuring options. There is no certainty that creditors will accept it, that funding will be secured or that any new trial will commence. For Paradigm, the independent review may have improved the case for preserving the asset, but it has not yet solved the question of who will pay to test it.

Get ASX:PAR news the moment it breaks

Instant push notifications No waitlist Free
Download on the App Store iPhone & iPad
Get it on Google Play Android
Email alerts

Bottom Line?

The independent ROW signal gives Paradigm a clinical proposition to take to creditors and regulators, but the next decisive evidence may be financial rather than medical.

Questions in the middle?

  • Will creditors support a funded restructuring that preserves the iPPS program?
  • Can Paradigm reconcile the interim exploratory findings into an agreed trial design with regulators?
  • Will further review explain the US data-quality and treatment-delivery issues well enough to justify another US study?

Sources

1